Pillar Biosciences partners with LSI Medience for lung cancer screening
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
2,000-Patient Lung Cancer Project Turns to Liquid Biopsy for Genomic Screening
The two-year project in Japan will use cfDNA and cfRNA testing to identify genomic alterations in patients with lung cancer. Pillar Biosciences, LC-SCRUM-Asia, and LSI Medience Corp announced a collaboration to support genomic screening of blood-based samples from patients with lung cancer as part of the LC-SCRUM-Asia project in Japan. Following approval of a revision to the LC-SCRUM-Asia project protocol, the participating organizations plan to…
Pillar Biosciences partners with LSI Medience for lung cancer screening
NATICK, Mass. and TOKYO, Aug. 20, 2026 /PRNewswire/ -- Pillar Biosciences, Inc. ("Pillar"), LC-SCRUM-Asia and LSI Medience Corporation ("LSI Medience") today announced a collaboration to support genomic screening of blood-based samples from patients with lung cancer as part of the LC-SCRUM-Asia project in Japan. Following approval of a revision to the LC-SCRUM-Asia project protocol, the participating organizations plan to begin testing in August…
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
